MOUNTAIN VIEW, Calif., Jan. 22 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software and strategic services for optimizing clinical drug development, today announced that Jonathan Kuwabara-Wagg, M.D., Ph.D., Senior Scientist, Strategic Consulting Services, will speak to industry leaders, regulators, and academics attending an open forum on "Sharing Knowledge to Improve Clinical Drug Development and Regulatory Decisions." The symposium, co-sponsored by the Drug Information Association (DIA) and the Food and Drug Administration (FDA), will be held at the Washington DC Marriott Hotel on January 24-25, 2007.
Dr. Wagg will give a presentation on prospects and challenges for sharing drug-disease models, along with pharmaceutical scientists from industry and academia, as part of an industry session and ensuing panel discussion. The session will include case examples of integrated disease modeling and will describe research on how modeling and simulation has been used to make best use of prior clinical information for drug development and approval decisions. The session will also offer a forum for interdisciplinary panel, audience and FDA discussion on areas of opportunity in the drug development and approval process presented by the Critical Path Initiative. Additional information can be found at http://www.diahome.org .
"The prospect of sharing pre-competitive disease, drug and clinical trial models is potentially attractive as a means for realizing elements of FDA's Critical Path vision," said Shawn O'Connor, Pharsight President, CEO and chairman. "Pharsight is pleased to participate in this distinguished gathering to discuss opportunities and challenges for sharing model-based information. We look forward to contributing to these important industry discussions and to exchanging perspectives with fellow practitioners and colleagues."
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com .
NOTE: Pharsight(R) is a registered trademark of Pharsight Corporation.
Pharsight CorporationCONTACT: investors, Douglas Sherk or Jennifer Beugelmans, +1-415-896-6820,or media, Jen Saunders, +1-646-201-5431, all of EVC Group for PharsightCorporation
Web site: http://www.pharsight.com/
